Table 2. The association between the change in plasma EV synaptic protein abundance (between baseline and follow-up) with the change in clinical severity in motor and cognitive domains (between baseline and follow-up) in people with Parkinson’s disease.

A generalized linear model was employed, and the data is presented as coefficient (p-value).

	UPDRS-II	UPDRS-III	Tremor	AR	PIGD	MMSE	MoCA
SNAP-25 * follow-up	0.218 (0.049)	0.312 (0.076)	0.004 (0.432)	0.016 (0.066)	0.009 (0.440)	–0.007 (0.932)	0.048 (0.647)
GAP-43 * follow-up	0.984 (0.031)	1.711 (0.018)	0.001 (0.972)	0.089 (0.011)	0.073 (0.115)	–0.099 (0.767)	–0.054 (0.901)
Synaptomagtin-1 * follow-up	1.543 (0.012)	2.205 (0.024)	0.007 (0.815)	0.107 (0.023)	0.109 (0.080)	–0.361 (0.421)	–0.260 (0.661)

UPDRS = Unified Parkinson's Disease Rating Scale; AR = akinetic rigidity; PIGD = postural instability and gait disturbance; MMSE = Mini-Mental Status Examination; MoCA = Montreal Cognitive Assessment.